(Q53253771)

12 May 2018

title

A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors. (English)

1 reference

12 May 2018

author name string

A W Tolcher

1

1 reference

12 May 2018

J C Bendell

2

1 reference

12 May 2018

K P Papadopoulos

3

1 reference

12 May 2018

H A Burris

4

1 reference

12 May 2018

A Patnaik

5

1 reference

12 May 2018

S F Jones

6

1 reference

12 May 2018

D Rasco

7

1 reference

12 May 2018

D S Cox

8

1 reference

12 May 2018

M Durante

9

1 reference

12 May 2018

K M Bellew

10

1 reference

12 May 2018

J Park

11

1 reference

12 May 2018

N T Le

12

1 reference

12 May 2018

J R Infante

13

1 reference

12 May 2018

publication date

24 October 2014

1 reference

12 May 2018

published in

Annals of Oncology

1 reference

12 May 2018

volume

26

1 reference

12 May 2018

page(s)

58-64

1 reference

12 May 2018

issue

1

1 reference

12 May 2018

Ras signaling and therapies

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU482

mTOR signaling in growth control and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU482

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU482

Prognostic and predictive roles of KRAS mutation in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU482

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU482

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU482

Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU482

Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU482

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU482

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU482

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU482

Everolimus for advanced pancreatic neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU482

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU482

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU482

Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU482

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU482

Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU482

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDU482

1 reference

12 May 2018

release_buflshkqlbef5gy5bnggdrrvh4

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/buflshkqlbef5gy5bnggdrrvh4

mapped directly with Wikidata item

24 November 2022

based on heuristic

PubMed ID

25344362

1 reference

12 May 2018